Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13631881 | 1.00 | TGFBR1 (0.31) | TGFBR1PRKCA | |
| SCHEMBL13227959 | 1.00 | TGFBR1 (0.31) | TGFBR1PRKCA | |
| SCHEMBL24024096 | 0.83 | — | — | |
| SCHEMBL23813407 | 0.83 | — | — | |
| SCHEMBL22872306 | 0.82 | CA1 (0.32) | — | |
| SCHEMBL10061083 | 0.82 | CA1 (0.32) | — | |
| SCHEMBL26352875 | 0.82 | CA1 (0.32) | — | |
| SCHEMBL18964003 | 0.80 | HSP90AA1 (0.31) | — | |
| SCHEMBL12632051 | 0.80 | GRN (0.33) | — | |
| SCHEMBL686067 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279053-A1 | GLP-1 RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20170218085-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | NOVARTIS AG (CH) | 2017-08-03 | — | — | US | disclosed |
| US-9585970-B2 | Site-specific labeling methods and molecules produced thereby | NOVARTIS AG (CH) | 2017-03-07 | — | — | US | disclosed |
| WO-2011156003-A2 | PEPTOID AND SYNTHETIC OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279053-A1 | GLP-1 RECEPTOR ANTAGONISTS | GLP1R, GIPR, GCGR | TGFBR1 208/4885PRKCA 703/4885 |
| US-20170218085-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | PTMS, DNPEP, PSAT1 | TGFBR1 4610/4885PRKCA 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.